Board of Directors

Sam Lanyon

Executive Chair

Sam Lanyon has more than 25 years of experience in strategy, sales and operations with a demonstrated track record in the global commercialization of technology rich healthcare products. Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. He also serves as a Non-Executive Director of Visus Therapeutics, a clinical-stage company focused on developing innovation medicines to improve vision. Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation, and ASX listed Vision Systems Ltd where he was responsible for establishing Vision Biosystem’s sales, marketing, and service operations throughout the EU, Middle East, Latin America, and Asia Pacific.

Mr. Lanyon holds an Honours degree in Mechanical Engineering from the University of Melbourne, a Post Graduate Diploma in Management from Melbourne Business School and has completed strategy training from London Business School.

Rob Sambursky, MD

Executive Director

Rob Sambursky has more than 25 years of industry and clinical medical experience. He is one of the original founders and Chief Executive of RPS Diagnostics, and currently leads Lumos Diagnostics as its President and Chief Executive Officer. He has served as the acting Chief Medical Officer for both RPS Diagnostics and for Lumos Diagnostics. In addition, Dr. Sambursky is a member of the Lumos Diagnostics Board of Directors, PPK Solutions Board of Directors, and serves as the Chairman for Visus Therapeutics, Inc. Dr. Sambursky has a strong scientific and clinical background in medical sciences, ophthalmology and infectious disease. He has authored numerous patents and scientific papers, conceived a novel point-of-care (POC) diagnostic test platform, served as the clinical and regulatory interface that led to multiple POC diagnostic tests obtaining international regulatory clearances as well as U.S. FDA 510(k) clearances with CLIA waiver designations, and successfully built a team that commercialized multiple diagnostic tests in the U.S. and abroad.

Dr. Sambursky is a board-certified ophthalmologist with fellowship training in refractive surgery and corneal external and infectious disease. He earned a BA in Biology from Brown University, an MA in Medical Sciences with concentrations in biochemistry and microbiology from Boston University and an MD from Boston University School of Medicine. Dr. Sambursky completed his internal medicine internship at Harvard’s Mount Auburn Hospital and both his ophthalmology residency and cornea fellowship at Wills Eye Hospital in Philadelphia.

Bronwyn Le Grice

Non-Executive Director

Bronwyn Le Grice has more than 18 years of executive experience in the health technology sector spanning commercialization, venture capital, corporate development, capital raising and industry advocacy.

Formerly an Investment Director with leading healthcare investment firm, BioScience Managers, Ms. Le Grice managed over $65M of private and public equity capital raisings and was actively involved in over $30M of portfolio investments. In 2017, she founded ANDHealth, Australia’s only dedicated digital health accelerator and commercialization support organization which has led to significant growth within Australia’s nascent digital health sector. Ms. Le Grice holds a number of health, technology and innovation advisory roles both in Australia and internationally. 

Ms. Le Grice has a Masters of Commercial Law from the University of Melbourne and a Bachelor of Commerce from the University of Western Australia.

Lawrence Mehren

Non-Executive Director

Lawrence Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. During his tenure, the company developed and launched its groundbreaking Accelerate Pheno™ instrument. Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics managing its four business units. He also held various global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr. Mehren was also Managing Director, Partner and Head of P&M Corporate Finance’s life sciences practice. 

Mr. Mehren holds an MBA from Northwestern University’s Kellogg Graduate School of Management and a BA in Political Science from the University of Arizona.

Catherine Robson

Non-Executive Director

Catherine Robson has more than 20 years of experience in management, finance and investment. Ms. Robson currently serves as a Non-Executive Director for ASX listed Equity Trustees (EQT Holdings Limited), where she is the chair of the Risk Committee and member of the Audit and Remuneration, Human Resources and Nominations Committees. Ms. Robson was previously a member of the Equity Trustees Superannuation Limited Board and served as the Chair of the Board Investment Committee.

Ms. Robson’s other Board appointments include serving as a Non-Executive Director for Australia’s sixth largest customer owned bank, Greater Bank, where she has been appointed as chair of the Risk Committee and is a member of the Audit Committee. She is also a Non-Executive Director of SCALE Investors, which invests early-stage venture capital in exceptional female led start-ups. 

Ms. Robson holds a Master of Laws, majoring in Tax, from Melbourne University as well as a Bachelor of Laws and BA in Asian Studies from The Australian National University. She has a Graduate Diploma in Applied Finance and is a graduate of the Australian Institute of Company Directors Course. 

Melanie Leydin

Company Secretary and Chief Financial Officer

Melanie Leydin has more than 25 years of experience in accounting and nearly 15 years of experience in company secretarial and corporate accounting roles for ASX listed companies.

Ms. Leydin is the co-founder and principal of Leydin Freyer, a practice that provides outsourced company secretarial and accounting services to public and private companies across a host of industries. She has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting and shareholder relations.

Ms. Leydin holds a Bachelor of Business from Swinburne University of Technology, majoring in accounting and corporate law and is a Fellow of the Governance Institute of Australia. She is a chartered accountant and a registered company auditor.